Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease
- 11 September 2019
- journal article
- letter
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (7) , 1149-1151
Abstract
We present five cases of choroidal neovascularization secondary to pediatric Best disease which were treated with two different doses of intravitreal ranibizumab. Optical coherence tomography was used for monitoring of the cases. Three cases had subretinal fibrosis at presentation and two out of these 3 cases required repeat intravitreal ranibizumab at one year follow-up due to recurrence of subfoveal subretinal fluid.Keywords
This publication has 4 references indexed in Scilit:
- Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of PrematurityOphthalmology, 2017
- Choroidal neovascularization secondary to Best’s vitelliform macular dystrophy in two siblings of a Malay familyClinical Ophthalmology, 2014
- Frequency, Genotype, and Clinical Spectrum of Best Vitelliform Macular Dystrophy: Data From a National Center in DenmarkAmerican Journal of Ophthalmology, 2012
- Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophyActa Ophthalmologica, 2008